

patients with UC.

CME/CE Credit Request Form

Stopping Ulcerative Colitis Progression in Its Tract: Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes

Live Symposium – Sunday, June 3, 2018

To receive CME/CE credit, you must complete all of this form and the evaluation form and turn them in to the CME Outfitters staff on your way out of the ballroom. Or you can fax it to: 614.448.4536. A certificate or statement of credit will be emailed to you within 4–6 weeks.

PLEASE PRINT CLEARLY (Form must be filled out completely to process CME/CE credit)										
First Name, MI, Last Name:										
Degree: O MD PA	O DO O PharmD	O RN	Other:							
Specialty: Gastroenterology	O Internal Medicine	O Primary Care	Othe	r:						
Complete mailing address:										
City:		State	e:	Zip:						
Business Phone:		Fax:								
Email (certificate or statement of cre										
Type of CE credit requested: O CM		urses (1.25) MOC (1.25)	○ CPE/Pharmacists (1.25) ○ MIPS Improvement (1.25)							
NABP e-Profile number (Pharmacist	s Only):		_ Month and da	y of birth (MM/DD):						
ABIM MOC profile number (Internal medicine physicians only): Month and day of birth (MM/DD):										
How did you learn about this contir	nuing education activity?									
O Postcard/direct mail	Email O Internet	Colleague	○ Fax	Other:						
As a result of my participation in	this activity, I commit to:									
• Use early, effective treatment to alter the progressive course of UC.										
• Utilize the AGA UC Care Pathway t	o treat my patients with UC to h	alt disease progression	n. y n							
 Incorporate disease activity monit 	oring strategies to facilitate opti	mal management of m	ny y n							



CME, CNE, ACPE, ABIM Activity Evaluation

Stopping Ulcerative Colitis Progression in Its Tract: Combining the Latest Evidence and Engaging Teaching Tools to Improve Patient Outcomes

Live Symposium – Sunday, June 3, 2018

To receive CME/CE credit, you must complete all of this form and the Credit Request Form and turn them in to the CME Outfitters staff on your way out of the ballroom. Or you can fax it to: 614.448.4536. A certificate or statement of credit will be emailed to you within 4–6 weeks.

1. The course met the stated objective(s):			Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
course of ulcerative collits (UC). 1 Utilize the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC. 1 Content Clinical Relevance 2 Content Clinical Relevance 3 Content Clinical Relevance 1 Content Clinical Relevance 2 Content Clinical Relevance 3 Content Clinical Relevance 4 Content Clinical Relevance 5 Content Clinical Relevance 6 Content Clinical Relevance 1 Content Clinical Relevance 1 Content Clinical Relevance 2 Content Clinical Relevance 3 Content Clinical Relevance 4 Content Clinical Relevance 5 Content Clinical Relevance 6 Content Clinical Relevance 9 Content Clinical Relevance 1 Content	1.						
progression in UC. Incorporate disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC. The following learning objectives pertain only to those requesting CNE or CPE credit: 1. Examine the rationale for the use of early, effective treatment in altering the progressive course of ulcerative collist (UC) 2. Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC. 2. Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC. 3. Describe disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC. 4. This activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC. 5. This activity provided me to have a better understanding of the topic(s). 6. This activity provided me to consider using the information in a different way to improve my practice. 7. This activity provided me with resources I can use in my daily practice or with my patients. 8. This activity will support my routine clinical practice to deliver evidence-based 8. This activity will support my routine clinical practice to deliver evidence-based 9. O O O O O O O O O O O O O O O O O O O			(5)	(4)	(3)	(2)	(1)
improvement, to facilitate optimal management of UC. The following learning objectives pertain only to those requesting CNE or CPE credit: - Examine the rationale for the use of early, effective treatment in altering the progressive - Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease - progression in UC. - Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease - progression in UC. - Describe disease activity monitoring strategies, including objective measures of disease - improvement, to facilitate optimal management of UC. 2. This activity monitoring strategies, including objective measures of disease - improvement, to facilitate optimal management of UC. 3. This activity monitoring strategies, including objective measures of disease - improvement, to facilitate optimal management of UC. 3. This activity monitoring strategies, including objective measures of disease - improvement, to facilitate optimal management of UC. 3. This activity assisted me to consider using the information in a different way to improve my practice. 4. This activity provided me with resources I can use in my daily practice or with my patients. 5. This activity will support my routine clinical practice to deliver evidence-based - best practice that improves patient health outcomes. 6. Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor): - Speaker - Content Clinical Relevance - David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) - Good -			5	4	3	2	1
 Examine the rationale for the use of early, effective treatment in altering the progressive course of ducerative colitis (UC) Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC. Describe disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC. This activity helped me to have a better understanding of the topic(s). This activity provided me to have a better understanding of the topic(s). This activity provided me with resources I can use in my daily practice or with my patients. This activity will support my routine clinical practice to deliver evidence-based on the formation in a different way to improve my practice. This activity will support my routine clinical practice to deliver evidence-based on the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor): Speaker Content Clinical Relevance David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) Quid T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) Quid T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) Quid T. Rubin, MD, FACG, AGAF, FACG, FACP Quid T. Rubin, MD, FACG, AGAF, FACG, FACQ Quid T. Rubi			5	4	3	2	1
course of ulcerative collisis (UC) Explain the AGA UC Care Pathway to guide personalized biologic therapy to halt disease progression in UC. Describe disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC. This activity helped me to have a better understanding of the topic(s). This activity sassisted me to consider using the information in a different way to improve my practice. This activity sassisted me to consider using the information in a different way to improve my practice. This activity will support my routine clinical practice to deliver evidence-based best practice that improves patient health outcomes. Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor): Speaker David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) (0.000 0.000 0.000			_	_	_	_	
progression in U.C. Described disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of U.C. This activity helped me to have a better understanding of the topic(s). This activity assisted me to consider using the information in a different way to improve my practice. This activity assisted me to consider using the information in a different way to improve my practice. This activity assisted me to consider using the information in a different way to improve my practice. This activity assisted me to consider using the information in a different way to improve my practice. This activity assisted me to consider using the information in a different way to improve my practice. This activity was included me with resources I can use in my daily practice or with my patients. This activity was practice the improves patient health outcomes. Excellently to 1 (Poor): Speaker Content Content Clinical Relevance Teaching Strategies Level of Expertise David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) To Will you change the way you practice based on this activity? This was all new information to me. Will you change the way you practice based on this activity? This was all new information to me. As compared to other CME activity was free of commercial bias? Approximately what percent of this content was NEW to you? 25% 50% 75% This was all new information to me. As compared to other CME activities you have participated in the past six months, do you believe this activity: Increased your knowledge Will improve patient outcomes in your practice.			_	_	_	_	1)
Describe disease activity monitoring strategies, including objective measures of disease improvement, to facilitate optimal management of UC. 2. This activity helped me to have a better understanding of the topic(s). 3. This activity assisted me to consider using the information in a different way to improve my practice. 4. This activity provided me with resources I can use in my daily practice or with my patients. 5. This activity will support my routine clinical practice to deliver evidence-based best practice that improves patient health outcomes. 6. Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor): Speaker David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) Miguel Regueiro, MD, AGAF, FACP, FASGE (moderator) Will you change the way you practice based on this activity? Will you change the way you practice based on this activity? Poor of the activity was balanced and objective? Approximately what percent of this content was NEW to you? 25% Approximately what percent of this content was NEW to you? 25% 50% This was all new information to me. 1. As compared to other CME activities you have participated in the past six months, do you believe this activity: In creased your knowledge Will improve patient outcomes in your practice. 9. Understanding the most useful information you gained from this activity? 1. Suggested topics for future activities: 1. Suggested topics for future activities: 1. Suggested topics for future activities:			5	4	3	2	1
3. This activity assisted me to consider using the information in a different way to improve my practice. 4. This activity provided me with resources I can use in my daily practice or with my patients. 5. This activity will support my routine clinical practice to deliver evidence-based best practice that improves patient health outcomes. 6. Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor): Speaker Content Clinical Relevance David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) Miguel Regueiro, MD, AGAF, FACG, FACP Will you change the way you practice based on this activity? Mill you change the way you practice based on this activity? Mill you change the activity was balanced and objective? Moo you feel the activity was free of commercial bias? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this content was NEW to you? Approximately what percent of this activity? Approximately what percent of this activity was all n		Describe disease activity monitoring strategies, including objective measures of disease	5	4	3	2	1
4. This activity provided me with resources I can use in my daily practice or with my patients. 5. This activity will support my routine clinical practice to deliver evidence-based best practice that improves patient health outcomes. 6. Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor): Speaker David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator)	2.	This activity helped me to have a better understanding of the topic(s).	5	4	3	2	1
S. This activity will support my routine clinical practice to deliver evidence-based best practice that improves patient health outcomes. 6. Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor): Speaker Content Clinical Relevance David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) (**) ① ② ② ① ② ② ② ② ② ② ② ② ② ② ② ② ② ② ②	3.	This activity assisted me to consider using the information in a different way to improve my practice	. 5	4	3	2	1
best practice that improves patient health outcomes. 6. Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor): Speaker Content Clinical Relevance David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) (a)	4.	This activity provided me with resources I can use in my daily practice or with my patients.	5	4	3	2	1
Speaker David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) Miguel Regueiro, MD, AGAF, FACG, FACP 7. Will you change the way you practice based on this activity? 9. 0 you feel the activity was balanced and objective? 9. Do you feel the activity was free of commercial bias? 9. Do you feel the activity was free of commercial bias? 9. Do you feel the activity was free of commercial bias? 1. As compared to other CME activities you have participated in the past six months, do you believe this activity: 1. Increased your knowledge Will improve patient outcomes in your practice 2. In the past 6 months, how many CME programs have you participated in? 1. Suggested topics for future activities: 1. Suggested topics for future activities:	5.		5	4	3	2	1
David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator)	6.	Rate the quality of the faculty member(s) listed below, from 5 (Excellent) to 1 (Poor):					
If no, please state reasons: 8. Do you feel the activity was balanced and objective?		David T. Rubin, MD, FACG, AGAF, FACP, FASGE (moderator) 54321 54321	54321 50		543	4321	
If no, please state reasons: 9. Do you feel the activity was free of commercial bias? 10. Approximately what percent of this content was NEW to you? 11. As compared to other CME activities you have participated in the past six months, do you believe this activity: 12. Increased your knowledge 13. What was the most useful information you gained from this activity? 14. Suggested topics for future activities: 15. If no, please state reasons: 16. If no, please state reasons: 17. If no, please state reasons: 18. If no, please state reasons:	7.	Tim you change the may you practice bases on this activity.					
0. Approximately what percent of this content was NEW to you?	8.	20 you real time detailed, may be and objective.					
1. As compared to other CME activities you have participated in the past six months, do you believe this activity: Increased your knowledge Will improve patient outcomes in your practice In the past 6 months, how many CME programs have you participated in? 1-4 5-10 11-15 Greater than 15 What was the most useful information you gained from this activity? 4. Suggested topics for future activities:	9.	Do you feel the activity was free of commercial bias? ① ①					
 ○ Increased your knowledge ○ Will improve patient outcomes in your practice 2. In the past 6 months, how many CME programs have you participated in? ○ 1-4 ○ 5-10 ○ 11-15 ○ Greater than 15 3. What was the most useful information you gained from this activity?	0.	Approximately what percent of this content was NEW to you?	5% 🔾	This was	all new in	formation	to me.
3. What was the most useful information you gained from this activity?	1.		this activi	ty:			
4. Suggested topics for future activities:	2.	In the past 6 months, how many CME programs have you participated in? \bigcirc 1-4 \bigcirc 5-10	O 1	1-15	Greate	r than 15	
	3.	What was the most useful information you gained from this activity?					
	4						
	4.						
	5.						